Omada Health (OMDA) Q1 2026: Member Base Surges 51% as PBM Partnerships Expand Platform Reach
Omada Health’s Q1 2026 marked a pivotal inflection in both scale and profitability, as member count surpassed 1 million and gross margin hit record highs. Strategic partnerships with all three major pharmacy benefit managers (PBMs) unlocked new commercial channels, while AI-driven operational leverage accelerated margin expansion. Raised guidance and early-stage program launches position Omada for durable, multi-year growth as employers broaden their approach to cardiometabolic care.
Summary
- PBM Channel Penetration: Omada’s integration with all top three PBMs cements distribution breadth for GLP-1 and cardiometabolic care.
- AI and Platform Scale: Automation and AI-powered care delivery are driving margin gains and operational efficiency.
- Guidance Lift: New partnerships and enrollment momentum set up Omada for sustained, high-quality growth into 2027.
Business Overview
Omada Health is a digital health company specializing in virtual care for chronic conditions, with a focus on cardiometabolic diseases such as diabetes, hypertension, obesity, and musculoskeletal (MSK) health. Revenue is generated through employer, health plan, and PBM contracts, with Omada paid to deliver measurable clinical outcomes for covered populations. Its business model combines a proprietary digital care platform, human coaching, and AI tools, with revenue diversified across prevention, GLP-1 support, and multi-condition care programs.
Performance Analysis
Q1 2026 delivered a step-change in both scale and profitability for Omada. Total members grew 51% year-over-year, surpassing 1 million for the first time—a direct result of expanded PBM and employer reach, improved enrollment conversion, and broad-based adoption across the cardiometabolic suite. GLP-1 care track adoption remained a key growth driver, but strong momentum continued in core diabetes and hypertension programs, signaling Omada’s ability to cross-sell and deepen engagement beyond weight management.
Margin expansion was equally notable, as gross margin rose to a record high, powered by AI-enabled care team productivity, operational leverage, and a higher share of mature (year two and beyond) members. The shift in member tenure profile—more members in later, higher-margin years—puts near-term pressure on average revenue per member but structurally boosts gross profit per member over time. Operating expenses declined as a percentage of revenue, reflecting disciplined investment and efficiency gains, while adjusted EBITDA turned positive in Omada’s most cost-intensive quarter, validating the scalability of its model.
- Enrollment Engine: Omada-led outreach and multi-channel marketing drove higher conversion rates, especially in diabetes and hypertension.
- AI Leverage: AI-powered tools reduced care team administrative burden and accelerated product development velocity.
- Commercial Wins: New large employer contracts and expanded PBM channel relationships diversified the revenue base and expanded covered lives.
Cash position remains strong with no debt, supporting further investment in platform capabilities and commercial expansion.
Executive Commentary
"The headline of the quarter is reach. In Q1, we saw the new investments in our GLP-1 capabilities begin to demonstrate traction. Omada is proud to join OptumRx's weight and gauge portfolio... Omada now has relationships with the nation's leading pharmacy benefits managers who serve most commercially insured lives and process 80% of prescription claims."
Sean Duffy, Co-founder and CEO
"Q1 was the strongest first quarter in Omada's history on members, on revenue, on gross margin, and on adjusted EBITDA... The leverage in our business continued to show as we delivered strong year-over-year gross margin expansion. Our GAAP gross profit was $49 million in Q1, representing a GAAP gross margin of 62%, up from 58% in Q1 25."
Steve Cook, Chief Financial Officer
Strategic Positioning
1. PBM Channel Integration
Omada now partners with all three major PBMs (OptumRx, CVS Caremark, and ESI), granting access to more than 70% of patients covered by these networks and 80% of all commercial prescription claims. This channel breadth enables Omada to meet employers wherever they are on the GLP-1 adoption curve, from those already covering anti-obesity medications to those seeking lower-cost alternatives or direct-to-employer models.
2. Platform Flexibility and Multi-Condition Penetration
Omada’s “portfolio strategy” allows it to address diverse employer needs, offering GLP-1 companion care, prescribing, and alternative access models. Multi-condition attach rates remain strong (40-50%), with cross-selling into hypertension, diabetes, and cholesterol programs amplifying both reach and member retention. Recent launches like the cholesterol program are already generating off-cycle deal wins, demonstrating the platform’s extensibility.
3. AI-Driven Operational Leverage
AI is now embedded across care delivery, engineering, and support, automating manual workflows and surfacing actionable insights for care teams. This has driven measurable improvement in care team productivity and member engagement (e.g., a 16% lift in meal tracking activity with AI-powered Meal Map), while accelerating product development and margin expansion. Management sees a path to exceed the current 70% long-term gross margin target, citing AI as a structural tailwind.
4. Evidence-Based Differentiation
Omada’s clinical credibility is reinforced by 30 peer-reviewed studies and third-party accreditations (NCQA, URAC), as well as a proprietary dataset from millions of care interactions. Recent analysis showed GLP-1 care track members lost 1.8x more weight and twice the body fat compared to controls, supporting employer ROI and sustaining outcomes post-therapy.
5. Durable Distribution and Data Moats
Longstanding relationships with leading employers, health plans, and PBMs create high switching costs and institutional trust, embedding Omada’s programs into benefit designs and workflows. Proprietary data and a co-intelligent care model (blending human and AI coaching) strengthen Omada’s competitive moat, supporting both product innovation and clinical outcomes.
Key Considerations
Omada’s Q1 2026 performance reflects a business reaching critical mass in both scale and operating leverage, with channel expansion and platform extensibility driving durable growth. Investors should weigh the following:
Key Considerations:
- Pipeline Visibility: Early-stage PBM and employer partnerships will take multiple cycles to fully ramp, with most incremental revenue from these deals expected in 2027 and beyond.
- Multi-Condition Retention: Increased penetration in diabetes and hypertension extends member tenure, structurally lifting gross margin over time even as revenue per member moderates.
- AI as Margin Catalyst: AI-driven automation is already translating into measurable care team efficiency and margin gains, with management signaling further upside to long-term margin targets.
- Enrollment Optimization: Omada-led outreach consistently outperforms client-led campaigns, with a majority of clients now adopting this model for higher yield rates.
- Platform Expansion: New program launches (e.g., cholesterol) are generating off-cycle deal momentum, validating the platform’s extensibility and cross-sell potential.
Risks
Omada faces several risks as it scales: Multi-year commercial relationships have long ramp times, creating lag between deal wins and revenue realization. Competition in digital health and GLP-1 care is intensifying, with other vendors also entering PBM and employer channels. Device shipping costs and macro volatility (e.g., conflict-driven logistics inflation) could pressure near-term margins, though current impact is minor. Regulatory shifts in drug coverage or employer benefit design could alter the pace of adoption for GLP-1 and related programs.
Forward Outlook
For Q2 2026, Omada guided to:
- Continued sequential revenue growth
- Stable or expanding adjusted EBITDA
For full-year 2026, management raised guidance:
- Revenue of $322 million to $330 million (prior: $312 million to $322 million)
- Adjusted EBITDA of $14 million to $20 million (prior: $7 million to $15 million)
Management highlighted several factors that support the outlook:
- Record new program launches and expanding commercial relationships, with most new revenue impact expected in 2027
- Ongoing AI-driven margin gains and operational leverage
Takeaways
Omada’s Q1 2026 signals a business entering a new phase of scale, with durable distribution, high engagement, and expanding margin profile.
- Channel Penetration: Full PBM integration unlocks a vast addressable market and cements Omada’s role as a connective tissue in employer benefit design.
- Margin Expansion: AI and operational leverage are already driving gross margin to record highs, with management forecasting further upside.
- Platform Growth: Investors should watch for ramping revenue from new PBM and employer programs in 2027, and ongoing expansion of multi-condition and new program attach rates.
Conclusion
Omada Health’s Q1 2026 results demonstrate a company scaling efficiently, with commercial reach, operational leverage, and clinical credibility reinforcing its competitive position. With raised guidance and a robust pipeline, Omada is positioned for durable growth as digital and pharmacological care converge in employer health benefits.
Industry Read-Through
Omada’s PBM channel wins and GLP-1 care model are a barometer for the broader digital health and chronic care sector, signaling that employers and payers are moving toward integrated, outcomes-driven platforms that blend virtual care, behavioral support, and medication management. AI’s rapid adoption in care delivery is now a real source of margin leverage, not just a future promise, and will likely become table stakes for competitors. As GLP-1 adoption accelerates, digital health vendors with proven multi-condition capabilities and deep PBM relationships will be best positioned to capture share, while point solutions or narrow verticals may face increasing pressure. Expect further consolidation and platform expansion as employers seek comprehensive, flexible solutions for complex chronic populations.